Menu

Speaking of Science

December 2015's selection of notable quotes

Dec 1, 2015
The Scientist Staff

OH, CANADA: Justin Trudeau (bottom row, center), Canada’s newly elected prime minister, has appointed the country’s first ever gender-equal cabinet, which includes Minister of Science Kirsty Duncan (top row, white jacket) and Minister of Innovation, Science, and Economic Development Navdeep Bains (middle row, far left).PRIME MINISTER OF CANADA/FLICKR

Because it’s 2015.

—Newly elected Canadian Prime Minister Justin Trudeau, responding to a reporter’s question about why he chose to appoint a gender-balanced cabinet, which included the country’s first-ever Minister of Science, a medical geographer named Kirsty Duncan, and Navdeep Bains, a businessman now serving as Minister of Innovation, Science, and Economic Development (November 4)

 

It feels fast, but we are going at the pace science allows.

Katrine Bosley, Editas Medicine CEO, describing why the company hopes to begin clinical trials of a CRISPR-based gene therapy in 2017, just four years after the first papers using the technique in human cells were published (November 5)

 

When I’m ninety, will I look back and be glad about what we have accomplished with this technology? Or will I wish I’d never discovered how it works?

—University of California, Berkeley, molecular biologist Jennifer Doudna, who helped develop CRISPR technology, on the need to exercise caution in the editing of human genes (November 16)

 

All of us who attempt to do science that breaks new ground are likely to make honest mistakes. Naturally we will try to make as few mistakes as possible, but it is inevitable that when we are working at the frontiers of knowledge, we will not always know which control experiments are necessary.

—Brandeis University neuroscientist Eve Marder, in an eLife article about the importance of acknowledging mistakes in science (October 22)

 

The distinction between brain and periphery is a bit outdated because the crosstalk is continuous.

Eve Van Cauter, University of Chicago neuroscientist, during a presentation of data on the links between metabolism, obesity, and sleep disturbances at this year’s Society for Neuroscience meeting in Chicago (October 17)

 

By eliminating federal funding for all aspects of this research, the NIH casts a shadow of negativity toward all experiments involving chimera studies regardless of whether human cells are involved. The current NIH restriction serves as a significant impediment to major scientific progress in the fields of stem cell and developmental biology and regenerative medicine and should be lifted as soon as possible.

—Stanford researcher Sean Wu, commenting on a renewed push to get the National Institutes of Health to lift its ban on funding for studies involving chimeric human/nonhuman embryos (November 5)

 

I’m the last person on the planet to say something is impossible, but I think, so far, [the idea of privacy] has been delusional.

—Harvard Medical School researcher George Church, commenting on a Global Alliance for Genomics and Health program in which patients’ genomic data are shared between research institutions and hospitals (October 29)

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!